Emesis responsive to levetiracetam

Lee, J W; Bromfield, Edward B; Kesari, Shreekant

doi:10.1136/jnnp.2007.142117

Cited by 6 publications

(2 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our data support antiemetic properties of LEV suggested by a case report 34 and a retrospective study reporting less chemotherapy-induced nausea and vomiting associated with use of LEV in patients with glioblastoma. 19 Limited by the study design, we cannot exclude that imbalances between groups such as steroid use with the potential to exert antiemetic effects ( Table 2 ) may have contributed to the reduced risk of nausea/vomiting during associated with LEV during maintenance treatment.…”

Section: Discussionsupporting

confidence: 90%

Associations of levetiracetam use with the safety and tolerability profile of chemoradiotherapy for patients with newly diagnosed glioblastoma

Seystahl

Oppong

Rhun

et al. 2022

Neuro-Oncology Advances

View full text Add to dashboard Cite

Background Levetiracetam (LEV) is one of the most frequently used antiepileptic drugs (AED) for brain tumor patients with seizures. We hypothesized that toxicity of LEV and temozolomide-based chemoradiotherapy may overlap. Methods Using a pooled cohort of patients with newly diagnosed glioblastoma included in clinical trials prior to chemoradiotherapy (CENTRIC, CORE, AVAglio) or prior to maintenance therapy (ACT-IV), we tested associations of hematologic toxicity, nausea or emesis, fatigue, and psychiatric adverse events during concomitant and maintenance treatment with the use of LEV alone or with other AED versus other AED alone or in combination versus no AED use at the start of chemoradiotherapy and of maintenance treatment. Results Of 1681 and 2020 patients who started concomitant chemoradiotherapy and maintenance temozolomide, respectively, 473 and 714 patients (28.1% and 35.3%) were treated with a LEV-containing regimen, 538 and 475 patients (32.0% and 23.5%) with other AED, and 670 and 831 patients (39.9% and 41.1%) had no AED. LEV was associated with higher risk of psychiatric adverse events during concomitant treatment in univariable and multivariable analyses (RR 1.86 and 1.88, p<0.001) while there were no associations with hematologic toxicity, nausea or emesis, or fatigue. LEV was associated with reduced risk of nausea or emesis during maintenance treatment in multivariable analysis (HR=0.80, p=0.017) while there were no associations with hematologic toxicity, fatigue, or psychiatric adverse events. Conclusions LEV is not associated with reduced tolerability of chemoradiotherapy in patients with glioblastoma regarding hematologic toxicity and fatigue. Antiemetic properties of LEV may be beneficial during maintenance temozolomide.

show abstract

Section: Discussionsupporting

confidence: 90%

Associations of levetiracetam use with the safety and tolerability profile of chemoradiotherapy for patients with newly diagnosed glioblastoma

Seystahl

Oppong

Rhun

et al. 2022

Neuro-Oncology Advances

View full text Add to dashboard Cite

show abstract

“…It has a rapid onset of action, does not require bloodlevel monitoring, is effective in treating both focal and generalized seizures, and is available in an extended release oral and dose equivalent intravenous formulation. Additionally, it has possible antiemetic properties 90 and was recently shown to inhibit O-6 methylguanine-DNA methyltransferase (MGMT) and potentially increase survival. 91,92 An increasing number of physicians who treat brain tumor patients recommend levetiracetam as the first-line AED in this population.…”

Section: Considerations In Selecting Antiepileptic Drugsmentioning

confidence: 99%

Epilepsy in glioma patients: mechanisms, management, and impact of anticonvulsant therapy: Table 1.

et al. 2015

View full text Add to dashboard Cite

Seizures are a well-recognized symptom of primary brain tumors, and anticonvulsant use is common. This paper provides an overview of epilepsy and the use of anticonvulsants in glioma patients. Overall incidence and mechanisms of epileptogenesis are reviewed. Factors to consider with the use of antiepileptic drugs (AEDs) including incidence during the disease trajectory and prophylaxis along with considerations in the selection of anticonvulsant use (ie, potential side effects, drug interactions, adverse effects, and impact on survival) are also reviewed. Finally, areas for future research and exploring the pathophysiology and use of AEDs in this population are also discussed.

show abstract

Zentrales Nervensystem

2015

Arzneimitteltherapie in Der Palliativmedizin

View full text Add to dashboard Cite

Emesis responsive to levetiracetam

Cited by 6 publications

References 8 publications

Associations of levetiracetam use with the safety and tolerability profile of chemoradiotherapy for patients with newly diagnosed glioblastoma

Associations of levetiracetam use with the safety and tolerability profile of chemoradiotherapy for patients with newly diagnosed glioblastoma

Epilepsy in glioma patients: mechanisms, management, and impact of anticonvulsant therapy: Table 1.

Zentrales Nervensystem

Contact Info

Product

Resources

About